Deploying 4P-Pharma startup studio’s model, mainly focusing on the development of promising Single Product Vehicles (SPVs).
Enriching internal pipeline with regenerated first-in-class products against serious untreated diseases.
Securing additional runaway to ensure company growth and operational agility.
Engaging towards external 4P-Pharma's growth through M&A and licensing- in- opportunities.

4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/

(Graphic: Business Wire)

With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.

Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."

This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.

This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.

Revital Rattenbach concludes: "After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community."

About 4P-Pharma

Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Site internet : https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma/

The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424933193/en/

Press Contacts
Financial Communication and Investor Relations
Jérôme Vailland – Chief Financial Officer
jerome.vailland@4p-pharma.com

Communication – Press Relations
Emmanuel Dadjé - Communication Manager
Emmanuel.dadje@4P-Pharma.com
Tel : +33 6 30 06 12 13

Logo

Images

Tags

More Like This

Jérôme Vailland Joins 4P-Pharma as Chief Financial Officer

Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million

415 Capital Announces €150 Million Second Fund and Key Appointments to Investment Committee to Support Breakthrough and Life-Saving Medical Innovation

4P-Pharma Welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as Independent Members of Its Board

Seroba Announces Above Target Final Close of its Fund IV at €123M ($134M)

4BIO Capital Strengthens Investment Team

Calliditas Therapeutics provides business update ahead of JP Morgan conference

From Molecule to Market and Beyond: Uniphar Announces Extended Global Commercialization Platform